Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Nature|November 6, 2019
Author Correction: Exome sequencing of Finnish isolates enhances rare-variant association powerAdam E Locke, Karyn Meltz Steinberg, Charleston W K Chiang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
NPJ Genomic Medicine|August 23, 2018
An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discoveryAlireza Haghighi, Joel B Krier, Agnes Toth-Petroczy, et al.
Journal of Critical Care|November 15, 2024
Shock prediction with dipeptidyl peptidase-3 and renin (SPiDeR) in hypoxemic patients with COVID-19Laurence W Busse, J Pedro Teixeira, Christopher L Schaich, et al.
Journal of the American Heart Association|February 29, 2024
Proteomic Associations of Adverse Outcomes in Human Heart FailureMarie-Joe Dib, Michael G Levin, Lei Zhao, et al.
Science (New York, N.Y.)|March 12, 2016
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart diseasePaolo Zanoni, Sumeet A Khetarpal, Daniel B Larach, et al.
Biorxiv : the Preprint Server for Biology|December 31, 2025
Complete genomes of a multi-generational pedigree to expand studies of genetic and epigenetic inheritanceMonika Cechova, Tamara A Potapova, Andreas Rechtsteiner, et al.
Plos Genetics|August 1, 2014
Distribution and medical impact of loss-of-function variants in the Finnish founder populationElaine T Lim, Peter Würtz, Aki S Havulinna, et al.
The Lancet. Diabetes & Endocrinology|July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialMikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trialMikhail N Kosiborod, Sheryl L Windsor, Orly Vardeny, et al.
Pageof 18